JP2024542950A5 - - Google Patents

Info

Publication number
JP2024542950A5
JP2024542950A5 JP2024523457A JP2024523457A JP2024542950A5 JP 2024542950 A5 JP2024542950 A5 JP 2024542950A5 JP 2024523457 A JP2024523457 A JP 2024523457A JP 2024523457 A JP2024523457 A JP 2024523457A JP 2024542950 A5 JP2024542950 A5 JP 2024542950A5
Authority
JP
Japan
Prior art keywords
sequence
raav
aav
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542950A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078327 external-priority patent/WO2023069967A2/en
Publication of JP2024542950A publication Critical patent/JP2024542950A/ja
Publication of JP2024542950A5 publication Critical patent/JP2024542950A5/ja
Pending legal-status Critical Current

Links

JP2024523457A 2021-10-18 2022-10-18 Cdkl5欠損症(cdd)の治療において有用な組成物 Pending JP2024542950A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256827P 2021-10-18 2021-10-18
US63/256,827 2021-10-18
PCT/US2022/078327 WO2023069967A2 (en) 2021-10-18 2022-10-18 Compositions useful in treatment of cdkl5 deficiency disorder (cdd)

Publications (2)

Publication Number Publication Date
JP2024542950A JP2024542950A (ja) 2024-11-19
JP2024542950A5 true JP2024542950A5 (cg-RX-API-DMAC7.html) 2025-10-20

Family

ID=86058644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523457A Pending JP2024542950A (ja) 2021-10-18 2022-10-18 Cdkl5欠損症(cdd)の治療において有用な組成物

Country Status (11)

Country Link
US (1) US20240425882A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419690A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024542950A (cg-RX-API-DMAC7.html)
KR (1) KR20240100490A (cg-RX-API-DMAC7.html)
CN (1) CN118401667A (cg-RX-API-DMAC7.html)
AU (1) AU2022369293A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235593A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006328A2 (cg-RX-API-DMAC7.html)
IL (1) IL312241A (cg-RX-API-DMAC7.html)
MX (1) MX2024004723A (cg-RX-API-DMAC7.html)
WO (1) WO2023069967A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7862321B2 (ja) * 2020-04-27 2026-05-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Cdkl5欠損症(cdd)の治療において有用な組成物
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same
WO2026096611A1 (en) * 2024-10-30 2026-05-07 Neurocrine Biosciences, Inc. Compositions and methods for delivering cyclin-dependent kinase-like 5 protein
WO2026096600A1 (en) * 2024-10-30 2026-05-07 Neurocrine Biosciences, Inc. Compositions and methods for delivering cyclin-dependent kinase-like 5 protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
LT3700570T (lt) * 2017-10-23 2025-04-10 Stoke Therapeutics, Inc. Priešprasmiai oligomerai, skirti būklių ir ligų, pagrįstų nonsens kodono nulemta mrnr degradacija, gydymui
MX2021007600A (es) * 2018-12-21 2021-08-11 Univ Pennsylvania Composiciones para la reduccion de la expresion transgenica especifica de drg.
WO2020219766A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
JP7697943B2 (ja) * 2019-10-23 2025-06-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 導入遺伝子発現のdrg特異的低減のための組成物
WO2021087282A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
JP7862321B2 (ja) * 2020-04-27 2026-05-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Cdkl5欠損症(cdd)の治療において有用な組成物

Similar Documents

Publication Publication Date Title
JP2022530544A5 (cg-RX-API-DMAC7.html)
JP2022530656A5 (cg-RX-API-DMAC7.html)
JP2022530633A5 (cg-RX-API-DMAC7.html)
CA3054131C (en) Modified aav capsid proteins and uses thereof
EP3635108B1 (en) Enhancing agents for improved cell transfection and/or raav vector production
JP2021515548A5 (cg-RX-API-DMAC7.html)
US7220577B2 (en) Modified AAV
JP2022531861A5 (cg-RX-API-DMAC7.html)
US20170067028A1 (en) Radiolabeling of adeno associated virus
JP2021522813A (ja) プラスミドを用いないaavベクター産生細胞株
JP2022507534A5 (cg-RX-API-DMAC7.html)
WO2021034222A1 (ru) Выделенный модифицированный белок vp1 капсида aav5
JP2023537625A5 (cg-RX-API-DMAC7.html)
JP2023526310A5 (cg-RX-API-DMAC7.html)
JP2025513066A5 (cg-RX-API-DMAC7.html)
CN113195719A (zh) 用于增加蛋白质表达和/或治疗单倍剂量不足症的方法及组合物
JP2023545830A5 (cg-RX-API-DMAC7.html)
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
JP2022530095A5 (cg-RX-API-DMAC7.html)
JP2022553406A5 (cg-RX-API-DMAC7.html)
JP2023550581A5 (cg-RX-API-DMAC7.html)
JP2022552892A5 (cg-RX-API-DMAC7.html)
JP2022542829A5 (cg-RX-API-DMAC7.html)
WO2024015877A9 (en) Novel aav3b capsid variants with enhanced hepatocyte tropism
RU2820088C1 (ru) Выделенный модифицированный белок VPI капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе